Search

Your search keyword '"Pautas C"' showing total 245 results
Start Over Author "Pautas C"
245 results on '"Pautas C"'

2. P404: PROGNOSTIC IMPACT OF CEBPA-MUTATIONAL SUBGROUPS IN ADULT AML – RESULTS OF A LARGE METAANALYSIS IN MORE THAN 1000 CEBPA-MUTANT PATIENTS

Author

Georgi, J.-A., primary, Stasik, S., additional, Kramer, M., additional, Röllig, C., additional, Haferlach, T., additional, Valk, P., additional, Linch, D., additional, Herold, T., additional, Duployez, N., additional, Taube, F., additional, Platzbecker, U., additional, Serve, H., additional, Baldus, C., additional, Müller-Tidow, C., additional, Haferlach, C., additional, Meggendorfer, M., additional, Koch, S., additional, Boertjes, E. L., additional, Hills, R. K., additional, Burnett, A., additional, Ehninger, G., additional, Metzeler, K., additional, Rothenberg-Thurley, M., additional, Dufour, A., additional, Dombret, H., additional, Pautas, C., additional, Fenwarth, L., additional, Bornhäuser, M., additional, Gale, R., additional, and Thiede, C., additional

Published
2022
Full Text
View/download PDF

31. How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome

Author

UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Yafour, N., Beckerich, F., Bulabois, C.E., Chevallier, P., Daguindau, E., Dumesnil, C., Guillaume, T., Huynh, A., Masouridi Levrat, S., Menard, A.L., Pautas, C., Poiré, X., Ravinet, A., Michallet, M., Bazarbachi, A., UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Yafour, N., Beckerich, F., Bulabois, C.E., Chevallier, P., Daguindau, E., Dumesnil, C., Guillaume, T., Huynh, A., Masouridi Levrat, S., Menard, A.L., Pautas, C., Poiré, X., Ravinet, A., Michallet, M., and Bazarbachi, A.

Abstract

Disease relapse remains the first cause of mortality of hematological malignancies after allogeneic hematopoietic stem cell transplantation (allo-HCT). The risk of recurrence is elevated in acute myeloid leukemia (AML) patients with high-risk cytogenetic or molecular abnormalities, as well as when allo-HCT is performed in patients with refractory hematological malignancies or with persistent molecular or radiological (PET-CT scan) residual disease. For high risk AML and myelodysplasia (MDS), a post transplant maintenance strategy is possible, using hypomethylating agents or tyrosine kinase inhibitors (TKI) anti-FLT3 when the target is present. For Philadelphia positive acute lymphoblastic leukemia (ALL), there is a consensus for the use of TKI anti BCR-ABL as post transplant maintenance.

Published
2017

32. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction

Author

Ramos F., Maurillo L., Itzykson R., Bargay J., Stauder R., Venditti A., Seegers V., Gaidano G., Gardin C., Musto P., Greil R., Sánchez-Guijo F., Fenaux P., Thépot S., Récher C., Raffoux E., Quesnel B., Delaunay J., Cluzeau T., Koka A.M., Stamatoullas A., Chaury M.-P., Gyan E., Cheze S., Banos A., Morel P., Plantier I., Taksin A.-L., Shanti A., Sanhes L., De Botton S., Marolleau J.P., Pautas C., Wattel E., Isnard F., Guerci A., Vey N., Dreyfus F., Ifrah N., Ades L., Martínez-Robles V., Debén G., Garrido A., Casaño J., Salamero O., Bergua J.M., Colado E., García R., Pedro C., Redondo S., Tormo M., Bonanad S., Díez-Campelo M., Pérez-Encinas M., de la Fuente A., Xicoy B., Falantes J.F., Font P., González-López T.J., Martín-Núñez G., Montesinos P., Pleyer L., Burgstaller S., Schreder M., Tinchon C., Pfeilstoecker M., Steinkirchner S., Melchardt T., Mitrovic M., Girschikofsky M., Lang A., Krippl P., Sliwa T., Egle A., Linkesch W., Voskova D., Angermann H., Spagnoli A., Lunghi M., Pietrantuono G., and Villani O.

Subjects
blood toxicity, cancer patient, leukocyte count, very elderly, retrospective study, blast cell, ear disease, cytogenetics, middle aged, neurotoxicity, Leukemia, antineoplastic antimetabolite, Aged, 80 and over, adult, nephrotoxicity, European ALMA score, clinical trial, acute granulocytic leukemia, aged, Leukemia, Myeloid, Acute, female, Italy, priority journal, validation study, drug withdrawal, Azacitidine, France, survival rate, Antimetabolites, Antineoplastic, overall survival, cardiotoxicity, Article, eye toxicity, multiple cycle treatment, remission, male, follow up, Humans, controlled study, drug fatality, human, gastrointestinal toxicity, survival time, lung toxicity, human cell, practice guideline, Australia, scoring system, treatment response, hearing impairment, major clinical study, skin toxicity, mortality, infection, multicenter study, Spain, treatment outcome, population research, musculoskeletal disease, Follow-Up Studies
Abstract

Hypomethylating agents are able to prolong the overall survival of some patients diagnosed with acute myeloid leukemia. The aim of this study was to evaluate the clinical use of azacitidine as front-line therapy in unfit acute myeloid leukemia (AML) patients and to develop a clinical prediction model to identify which patients may benefit more from the drug. One hundred and ten untreated unfit AML patients received front-line azacitidine therapy in Spain, and response and survival were evaluated in them following European LeukemiaNet (ELN) guidelines. A clinical prediction rule was obtained from this population that was validated and refined in 261 patients treated in France, Austria and Italy. ELN response was achieved in 21.0% of the 371 patients (CI95% 17.0-25.5) and did not depend on bone marrow blast cell percentage. Median overall survival was 9.6 months (CI95% 8.5-10.8) and 40.6% of the patients were alive at 1 year (CI95% 35.5-45.7). European ALMA score (E-ALMA), based on performance status, white blood cell counts at azacitidine onset and cytogenetics, discriminated three risk groups with different survival and response rates. Azacitidine seems a reasonable therapeutic option for most unfit AML patients, i.e. those displaying a favorable or intermediate E-ALMA score. © 2014 Elsevier Ltd.

Published
2015
Full Text
View/download PDF

33. Infiltrats de reconstitution lymphocytaire avec des lymphocytes atypiques mimant un lymphome T cutané ou une lymphoprolifération CD30 : 12 cas

Author

Hurabielle, C., primary, Sbidian, E., additional, Beltraminelli, H., additional, Bouchindhomme, B., additional, Chassagne-Clément, C., additional, Balme, B., additional, Bossard, C., additional, Delfau-Larue, M.-H., additional, Wolkenstein, P., additional, Chosidow, O., additional, Robin, C., additional, Cordonnier, C., additional, Toma, A., additional, Pautas, C., additional, and Ortonne, N., additional

Published
2016
Full Text
View/download PDF

34. Disease status and stem cell source impact on the results of reduced intensity conditioning transplant for Hodgkin lymphoma: a retrospective study from the French Society of Bone Marrow Graft Transplantation and Cellular Therapy

Author

Marcais, Ambroise, Porcher, Raphael, Robin, Marie, Mohty, Mohamad, Michalet, Mauricette, Blaise, Didier, Tabrizi, Reza, Clement, Laurence, Ceballos, Patrice, Daguindau, Etienne, Bilger, Karin, Dhedin, Nathalie, Lapusan, Simona, Bay, Jacques Olivier, Pautas, C Eacutecile, Garban, Frederic, Ifrah, Norbert, Guillerm, Gaelle, Contentin, Nathalie, Bourhis, Jean-Henri, Yakoub Agha, Ibrahim, Bernard, Marc, Cornillon, Jerome, Milpied, Noel, Biostatistique et épidemiologie clinique, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hématologie greffe [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Haut-Lévêque, Université Sciences et Technologies - Bordeaux 1-CHU Bordeaux [Bordeaux], Service d'hématologie et oncologie médicale, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie-Université de Montpellier (UM), Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), TheREx, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-Département de cancérologie et d'hématologie, CHU Grenoble-Hôpital Michallon-CHU Grenoble-Hôpital Michallon, Service d'hématologie clinique [Avicenne], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13)-Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service Hématologie, Hôpital Morvan [Brest]-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Laboratoire Hubert Curien [Saint Etienne] (LHC), Institut d'Optique Graduate School (IOGS)-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), Institut de Cancérologie de la Loire Lucien Neuwirth, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Haematology, and CHU Bordeaux [Bordeaux]

Subjects
[SDV.CAN]Life Sciences [q-bio]/Cancer
Abstract

International audience; The role of reduced intensity allogeneic stem cell transplantation for the treatment of relapsed/refractory Hodgkin lymphoma remains controversial. We retrospectively analyzed 191 patients who underwent reduced intensity allogeneic stem cell transplantation between 1998 and 2008 for relapsed or refractory Hodgkin lymphoma and whose data were reported to the French registry. Median follow-up was 36 months. Estimated 3 years overall survival, progression free survival, cumulative incidence of relapse and cumulative incidence of non relapse mortality were 63%, 39%, 46%, and 16% respectively. There was no difference in outcome between patients in complete response and in partial response at time of transplantation for overall survival (70% versus 74%, no significant difference) and progression free survival (51% versus 42%, no significant difference). Patients with chemoresistant disease had a shorter overall survival (39% at 3 years p=0.0003) and progression free survival (18% at 3 years p=0.001) than patients in complete remission. The use of umbilical cord blood as stem cell source was associated with a poor outcome with an increased risk of death with a hazard ratio of 3.49 (95% confidence interval 1.26 to 9.63, p=0.016). The use of peripheral blood was associated with a better outcome for patients who where alive after 1 year post transplantation with a hazard ration of 0.38 (95% confidence interval 0.17 to 0.83, p=0.016). Disease status at transplantation remains the most important risk factor for outcome. Our data suggest that the use of peripheral blood should be preferred whereas umbilical cord blood should be used with caution.

Published
2013
Full Text
View/download PDF

35. Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial

Author

Boissel, N., primary, Renneville, A., additional, Leguay, T., additional, Lefebvre, P. C., additional, Recher, C., additional, Lecerf, T., additional, Delabesse, E., additional, Berthon, C., additional, Blanchet, O., additional, Prebet, T., additional, Pautas, C., additional, Chevallier, P., additional, Lepretre, S., additional, Girault, S., additional, Bonmati, C., additional, Guieze, R., additional, Himberlin, C., additional, Randriamalala, E., additional, Preudhomme, C., additional, Jourdan, E., additional, Dombret, H., additional, and Ifrah, N., additional

Published
2015
Full Text
View/download PDF

36. Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia

Author

Peterlin, P., primary, Renneville, A., additional, Ben Abdelali, R., additional, Nibourel, O., additional, Thomas, X., additional, Pautas, C., additional, de Botton, S., additional, Raffoux, E., additional, Cayuela, J.-M., additional, Boissel, N., additional, Terre, C., additional, Celli-Lebras, K., additional, Castaigne, S., additional, Preudhomme, C., additional, Gardin, C., additional, and Dombret, H., additional

Published
2014
Full Text
View/download PDF

37. Microsatellite instability and frameshift mutations in BAX and transforming growth factor-beta RII genes are very uncommon in acute lymphoblastic leukemia in vivo but not in cell lines

Author

Jj, Molenaar, Gérard B, Chambon-Pautas C, Hélène Cavé, Duval M, Vilmer E, Grandchamp B, and Other departments

Subjects
Proto-Oncogene Proteins c-bcl-2, Transforming Growth Factor beta, Proto-Oncogene Proteins, Biomarkers, Tumor, Tumor Cells, Cultured, Humans, DNA, Satellite, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Frameshift Mutation, bcl-2-Associated X Protein
Abstract

Mutations in the DNA mismatch repair (MMR) system lead to an instability of simple repetitive DNA sequences involved in several cancer types. This instability is reflected in a high mutation rate of microsatellites, and recent studies in colon cancer indicate that defects in MMR result in frequent frameshift mutations in mononucleotide repeats located in the coding regions of BAX and transforming growth factor-beta (TGF-beta) receptor genes. Circumstantial evidence suggests that the MMR defect may be involved in some lymphoid malignancies, although several allelotype analyses have concluded on the low level of microsatellite instability in acute lymphoblastic leukemias. To further evaluate the implication of MMR defects in leukemogenesis, we have studied a series of 98 children with acute lymphoblastic leukemia and 14 leukemic cell lines using several indicators of MMR defects. Microsatellite markers were compared between blast and normal DNA from the same patients and mutations were sought in mononucleotide repeat sequences of BAX and TGF-beta receptor II (TGF-beta RII). The absence of microsatellite instability (MI) and the absence of mutations in the genes examined from patient's leukemic cells contrasted with the observation that half of the cell lines displayed a high degree of MI and that three of seven of these mutator cell lines harbored mutations in BAX and/or TGF-beta RII. From these results we conclude that MMR defects are very uncommon in freshly isolated blasts but are likely to be selected for during the establishment of cell lines.

Published
1998

38. Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Author

Marcais, A., primary, Porcher, R., additional, Robin, M., additional, Mohty, M., additional, Michalet, M., additional, Blaise, D., additional, Tabrizi, R., additional, Clement, L., additional, Ceballos, P., additional, Daguindau, E., additional, Bilger, K., additional, Dhedin, N., additional, Lapusan, S., additional, Bay, J.-O., additional, Pautas, C., additional, Garban, F., additional, Ifrah, N., additional, Guillerm, G., additional, Contentin, N., additional, Bourhis, J.-H., additional, Agha, I. Y., additional, Bernard, M., additional, Cornillon, J., additional, and Milpied, N., additional

Published
2013
Full Text
View/download PDF

47. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

Author

Taksin, A-L, primary, Legrand, O, additional, Raffoux, E, additional, de Revel, T, additional, Thomas, X, additional, Contentin, N, additional, Bouabdallah, R, additional, Pautas, C, additional, Turlure, P, additional, Reman, O, additional, Gardin, C, additional, Varet, B, additional, de Botton, S, additional, Pousset, F, additional, Farhat, H, additional, Chevret, S, additional, Dombret, H, additional, and Castaigne, S, additional

Published
2006
Full Text
View/download PDF

49. Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy

Author

Thomas, X, primary, Le, QH, additional, de Botton, S, additional, Raffoux, E, additional, Chelghoum, Y, additional, Pautas, C, additional, Dreyfus, F, additional, Dhedin, N, additional, Vekhoff, A, additional, Troncy, J, additional, Pigneux, A, additional, de Revel, T, additional, Reman, O, additional, Travade, P, additional, Thiebaut, A, additional, Guerci, A, additional, Elhamri, M, additional, Fenaux, P, additional, Dombret, H, additional, and Michallet, M, additional

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results